Stryker’s SonicAnchor aims at improving soft tissue repair

Cara Livernois | | Health Exec | Economics

Stryker's Foot & Ankle have developed a new way to treat soft tissue repair with their SonicAnchor technology.

SonicAnchor, a bioresorbable polylactide polymer, is an implant that uses ultrasonic energy to liquefy the tip of the device and fill in cancellous bone, offering a more structurally stable fixation in seconds and lowering the risk of breaking during insertion. Testing on the device has shown a vast improvement in the load stability when compared to current methods

The technology can be used to conduct a range of procedures including: including Achilles tendon repair, lateral and medial stabilization, hallux valgus reconstruction, midfoot reconstruction, metatarsal ligament repair and digital tendon transfer.

"SonicAnchor is transforming the soft tissue experience, and we are excited Stryker is leading the way in providing this innovative solution to orthopedic surgeons. Its SonicFusion technology is unlike any other on the market," said Tom Popeck, vice president and general manager of Stryker's Foot and Ankle.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Bipartisan group of 233 House members call for Medicare reform
Wartime powers enacted to address nationwide IV fluid shortage
Cardiologist compensation still rising, especially in invasive and interventional cardiology
Baxter begins importing IV supplies as 86% of providers report shortages
CMS proposes rule to combat gray market health insurance scams
Private equity firm buys controlling stake in Surescripts

Around the web

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup